Dermatomyositis with Fibrosing Alveolitis:
Response to Treatment with Cyclophosphamide P N Plowman MRCP5 and D E Stableforth MRCP2 (Brompton Hospital, London S W3 6HP) (for C M Ridley FRCP) (Whittington Hospital, London NJ9 5NF) Mr H W, a 29-year-old Jamaican negro, presented in April 1976 with a short history of fever, joint pains and stiffness and difficulty in sitting up. He was found to have cedema of the back of the right hand, diffuse scaling of the neck and extensor elbows and telangiectatic lesions of the nail folds. Three weeks later a profound, generalized (but predominantly proximal) muscle weakness supervened, and at that time, a short-lived discoloration of the eyelids was seen. The clinical diagnosis of dermatomyositis was supported by a serum creatine phosphokinase level of 108 iu/l (normal range 0-50) and an electromyogram showed polyphasic units and a reduced interference pattern with low voltage fibrillation potentials. The chest X-ray showed minimal irregular nodular right basal shadowing.
Treatment was started with prednisone 80 mg daily and there was a modest improvement in muscle power which relapsed as the dose was reduced, over a few weeks, to 40 mg daily. Shortly afterwards, the scaling areas on the elbows ulcerated (Fig 1) .
In July 1976, whilst on this dose of steroids, the patient noticed breathlessness. On examination of the chest, there were basal end-inspiratory crepitations; also radiologically bilateral lower zone nodular and confluent shadows had appeared (Fig 2A) . Lung function tests showed a mild restrictive defect but gas transfer per unit volume of lung (KCO) was markedly reduced (Table 1) . A trephine lung biopsy (October 1976) showed mild interstitial fibrosis with relatively few intraalveolar histiocytes in the biopsied specimen, and no evidence of pulmonary vasculitis (Fig 3) . This was compatible with a diagnosis of fibrosing alveolitis of a predominantly fibrotic type (Scadding & Hinson 1967) .
In November 1976, the patient (on prednisone 30 mg daily) became dyspnceic at rest. The muscle weakness was worse and elbow and perianal skin ulcerations, together with nail-fold and finger-pulp hemorrhages, suggested the presence of a vasculitic process. The chest signs were unchanged and there was no evidence of cardiac failure.
Pulmonary function testing in November 1976 showed an increased restrictive defect and further reduction in total gas transfer (Table 1) resting arterial hypoxaemia (PaO2 9.9 kPa). Diaphragmatic and intercostal muscle power were shown to be normal by the patient's ability to sustain positive and negative pressures against a mercury column of over 70 mm above and below zero. The electrocardiogram was abnormal and showed widespread S-T depression, T-wave inversion and left axis deviation.
Other Investigations (November 1976): Hb, 13.4 g/100 ml, Hb electrophoresis normal; white cell count, 11 500/mm3 (polymorphs 82 %); ESR, 64 mm in 1 hour (Westergren); serum electrolytes and creatinine, normal; total serum protein, 73 g/1; albumen, 35 g/l; immunoglobulins, IgG 226 iu (57-172), IgM 342 iu , IgA 186 iu (75-268); antinuclear antibody (ANA), negative; rheumatoid factor (RF), Rose Waaler 1/10; rheumatoid arthritis himagglutination assay, positive 1/640; smooth muscle, thyroid, mitochondrial, parietal cell autoantibodies, negative; serum C3 complement, 208,g/100 ml (70-180); cryoprecipitates, negative; Clq binding (Dr E J Holborrow & Dr I Mohammed), 51 % (20 %).
In November 1976, in view of the clinical deterioration, treatment was changed to cyclophosphamide 100 mg daily and d-penicillamine increasing by increments to 1 g daily. Prednisone was gradually reduced to 10 mg daily. There was steady improvement over the next few months with return to near normal muscle power, healing of the vasculitic lesions and reduced breathlessness on effort. The chest X-ray taken in March 1977 ( Fig 2B) showed reduced basal shadowing, and lung function improved particularly with respect to total lung capacity (TLC) and KCO (Table 1) .
Penicillamine therapy was discontinued in January 1977 after the development of a rash; his improvement continued whilst on cyclophosphamide 100 mg and prednisone 10 mg daily. 
Discussion
There are now reports associating fibrosing alveolitis and rheumatoid arthritis (Ellman & Ball 1948) , systemic lupus erythematosus (Eisenberg et al. 1973) , systemic sclerosis (Sackner 1966) and Raynaud's phenomenon (Spiro, Hodson & Turner-Warwick, in preparation) in conjunction with other immunological abnormalities. Rarely, fibrosing alveolitis has been reported with polymyositis (Thompson & Mackay 1970) and with dermatomyositis (Mills & Mathews 1956 , Sandbank et al. 1966 , Duncan et al. 1974 , Schwarz et al. 1976 . A Mayo Clinic study (Frazier & Miller 1974) suggested that it occurs in 5 0% of patients with polymyositis.
In the series of Duncan et al. (1974) the lung involvement followed the skin, joint and muscle changes in 6 out of 14 cases, although a vasculitic process was not reported in any of these. Similarly in our patient, the histologically-proven fibrosing alveolitis developed whilst he was on steroid therapy for the dermatomyositis. In our patient the ANA was negative in accord with the previous series (Duncan et al. 1974 , cf. Sharp et al. 1972 ) and the RF was positive in modest titre. The elevated Clq binding result suggested the presence of circulating immune complexes which might have been instrumental in the etiology of the observed digital vasculitis. Raynaud's phenomenon has been reported in 30 of patients with dermatomyositis and some of them have had lung involvement (Pearson 1966 The response of our patient to treatment by immune suppression with cyclophosphamide is documented here radiologically (Fig 2A & B) and physiologically (Table 1) . It has continued despite steroid reduction and after penicillamine withdrawal. Penicillamine, which interferes with collagen synthesis (Jayson 1975) and may reduce pulmonary fibrosis, was probably not helpful in this case.
The frequent failure of the pulmonary lesion in dermatomyositis to respond to corticosteroid therapy has been noted (Duncan et al. 1974) . Our experience of cyclophosphamide in this one case suggests a new approach to treatment.
